extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -51,7 +51,7 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
 ### Additional Evidence (challenge)
 *Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
 
-The Trump administration Medicare deal establishes $245/month pricing (82% below list) with narrow eligibility targeting high-risk comorbid patients (~10% of Medicare beneficiaries). This fundamentally changes the cost-effectiveness calculation: the 'inflationary through 2035' conclusion assumed higher prices and broader population. With narrow targeting to patients showing strongest evidence for downstream savings (kidney disease, cardiovascular, heart failure) and 82% price reduction, the net cost impact under capitated MA plans may be neutral or positive rather than inflationary.
+The Trump Administration Medicare deal reduces GLP-1 prices to $245/month (82% below list) with narrow eligibility targeting high-comorbidity patients (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). The $50/month out-of-pocket cap removes financial barriers for eligible Medicare beneficiaries. This pricing + targeting combination may shift the cost-effectiveness calculus: if adherence improves due to affordability AND spending is concentrated on patients where multi-organ protection generates highest savings (kidney disease, heart failure, CVD), the 'inflationary through 2035' conclusion may not hold for the Medicare population under capitated payment models.
 
 ---
 

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,12 +47,6 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
-
-### Additional Evidence (extend)
-*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
-
-The Medicare deal includes $50/month out-of-pocket maximum for tirzepatide starting April 2026, removing the primary financial barrier to persistence. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence more than previously understood. The $50 OOP cap may substantially improve the 15% two-year persistence rate by eliminating cost as a discontinuation factor.
-
 ---
 
 Relevant Notes:

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -41,7 +41,7 @@ The source does not provide granular income-stratified discontinuation rates, so
 ### Additional Evidence (confirm)
 *Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
 
-The Medicare deal's $50/month OOP cap explicitly addresses affordability as a persistence barrier. The deal structure (steep price reduction + low OOP cap) suggests policymakers view affordability as the primary persistence obstacle for Medicare beneficiaries, confirming that discontinuation is driven by cost rather than clinical factors.
+The Medicare GLP-1 deal includes a $50/month out-of-pocket maximum for tirzepatide (Zepbound) starting April 2026, explicitly designed to address affordability as a discontinuation driver. The deal structure acknowledges that price, not just clinical factors, determines persistence—the policy intervention directly targets the affordability barrier identified in prior research.
 
 ---
 

domains/internet-finance/futarchy-governed-memecoin-launchpads-face-reputational-risk-tradeoff-between-adoption-and-credibility.md

@@ -27,6 +27,12 @@ From the MetaDAO proposal:
 
 This claim extends futarchy-governed-permissionless-launches-require-brand-separation-to-manage-reputational-liability-because-failed-projects-on-a-curated-platform-damage-the-platforms-credibility by showing the reputational concern operates at the mechanism level, not just the platform level. The market's rejection of Futardio suggests futarchy stakeholders prioritize mechanism credibility over short-term adoption metrics.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16*
+
+Phonon Studio AI raised $88,888 target but ended in 'Refunding' status within one day (launched 2026-03-05, closed 2026-03-06). The project had live product traction (1000+ songs generated in first week, functional tokenized AI artist logic) but still failed to attract capital, suggesting futarchy-governed launches face quality perception issues even when projects demonstrate real product-market validation.
+
 ---
 
 Relevant Notes:

domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md

@@ -56,10 +56,16 @@ Hurupay raised $2,003,593 against a $3,000,000 target (67% of goal) and entered
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-03-futardio-launch-cloak]] | Added: 2026-03-16*
+*Source: 2026-03-03-futardio-launch-cloak | Added: 2026-03-16*
 
 Cloak raised only $1,455 against a $300,000 target (0.5% of target), entering refunding status. This represents a near-total failure of market validation, contrasting sharply with the 15x oversubscription pattern. The project had shipped product (live mainnet beta with Oro integration), had credible team (repeat builders, Superteam contributors), and addressed a real problem (MEV extraction on DCA orders). Despite these fundamentals, the futarchy-governed raise failed to attract capital, suggesting that product-market fit and team credibility are insufficient without pre-existing community or distribution.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16*
+
+Phonon Studio AI launch failed to reach its $88,888 target and entered refunding status, demonstrating that not all futarchy-governed raises succeed. The project had demonstrable traction (live product, 1000+ songs generated, functional token mechanics) but still failed to attract sufficient capital, suggesting futarchy capital formation success is not uniform across project types or market conditions.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json

@@ -1,13 +1,13 @@
 {
   "rejected_claims": [
     {
-      "filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md",
+      "filename": "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md",
       "issues": [
         "missing_attribution_extractor"
       ]
     },
     {
-      "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md",
+      "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md",
       "issues": [
         "missing_attribution_extractor"
       ]
@@ -19,12 +19,12 @@
     "fixed": 2,
     "rejected": 2,
     "fixes_applied": [
-      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16",
-      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md:set_created:2026-03-16"
+      "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:set_created:2026-03-16",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md:set_created:2026-03-16"
     ],
     "rejections": [
-      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor",
-      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md:missing_attribution_extractor"
+      "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:missing_attribution_extractor",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md:missing_attribution_extractor"
     ]
   },
   "model": "anthropic/claude-sonnet-4.5",

inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md

@@ -12,7 +12,7 @@ priority: high
 tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
 processed_by: vida
 processed_date: 2026-03-16
-enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
@@ -52,9 +52,9 @@ EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) change
 
 
 ## Key Facts
-- Medicare GLP-1 payment demonstration begins July 2026
-- BALANCE Model in Medicaid begins May 2026
-- BALANCE Model in Medicare Part D begins January 2027
-- Oral Wegovy launches January 2026 at $149-$299/month
-- Medicare beneficiaries pay $50/month OOP maximum for tirzepatide starting April 2026
+- Medicare GLP-1 coverage demonstration begins July 2026
+- BALANCE Model in Medicaid launches May 2026
+- BALANCE Model in Medicare Part D launches January 2027
+- Oral Wegovy launching January 2026 at $149-$299/month
 - Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria
+- $50/month out-of-pocket maximum for tirzepatide (Zepbound) for Medicare beneficiaries starting April 2026

inbox/archive/2026-03-05-futardio-launch-phonon-studio-ai.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/x1yqPH8mutuiqkrz66DPwFw1ykQqT4v5KyUUtUzBgPA"
 date: 2026-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["futarchy-governed-memecoin-launchpads-face-reputational-risk-tradeoff-between-adoption-and-credibility.md", "metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Launch Details
@@ -173,3 +177,13 @@ Phonon is already live which means there is real product market validation, meas
 - Token mint: `J697wnGGP8yWhYSrrMNsfH7cpKqp8up4uteigCHZmeta`
 - Version: v0.7
 - Closed: 2026-03-06
+
+
+## Key Facts
+- Phonon Studio AI launched on Futardio 2026-03-05 with $88,888 USDC target
+- Phonon Studio AI fundraise entered refunding status by 2026-03-06
+- Phonon generated 1000+ AI songs in first week of operation
+- Phonon uses Meteora Dynamic Bonding Pool protocol for artist token trading
+- Phonon proposed $11,777 monthly operational allowance
+- Phonon token: J69, mint address J697wnGGP8yWhYSrrMNsfH7cpKqp8up4uteigCHZmeta
+- Phonon launch address: x1yqPH8mutuiqkrz66DPwFw1ykQqT4v5KyUUtUzBgPA